TARGET PATHOGENS

ALTABAX is the topical antibacterial for impetigo that targets Staphylococcus aureus (methicillin-susceptible isolates only) and Streptococcus pyogenes in your patients.

ALTABAX is the first in a new and
different class of prescription
antibacterials — the pleuromutilins.

Learn more Learn more

Consumers

Get up to $15 off your prescription†

Is Your Skin Infection Impetigo?
Take this simple test and see your doctor

† subject to eligibility

Important Safety Information

ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.

The most common drug-related adverse reaction was application site irritation (1.4% of patients).

Please see complete Prescribing Information for ALTABAX

References:
  1. Kosowska-Shick K, Clark C, Credito K, et al. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 2006;50:765-769.
  2. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008;158:1077-1082.
  3. Data on file ABX107-01, GlaxoSmithKline.